[go: up one dir, main page]

IT1249051B - Immunotossina da anticorpi monoclonali anti-cd5 - Google Patents

Immunotossina da anticorpi monoclonali anti-cd5

Info

Publication number
IT1249051B
IT1249051B ITMI910491A ITMI910491A IT1249051B IT 1249051 B IT1249051 B IT 1249051B IT MI910491 A ITMI910491 A IT MI910491A IT MI910491 A ITMI910491 A IT MI910491A IT 1249051 B IT1249051 B IT 1249051B
Authority
IT
Italy
Prior art keywords
immunotoxin
monoclonal antibodies
momordine
obtainable
monoclonal antibody
Prior art date
Application number
ITMI910491A
Other languages
English (en)
Inventor
Giulia Porro
Daniela Modena
Fiorenzo Stirpe
Gianni Gromo
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Priority to ITMI910491A priority Critical patent/IT1249051B/it
Publication of ITMI910491A0 publication Critical patent/ITMI910491A0/it
Priority to PCT/EP1992/000338 priority patent/WO1992014491A1/en
Priority to EP92904825A priority patent/EP0577612A1/en
Priority to AU12088/92A priority patent/AU1208892A/en
Publication of ITMI910491A1 publication Critical patent/ITMI910491A1/it
Application granted granted Critical
Publication of IT1249051B publication Critical patent/IT1249051B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Si descrive un'immunotossina ottenibile per coniugazione covalente della tossina di origine vegetale momordina a un anticorpo monoclonale anti-CD5.
ITMI910491A 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5 IT1249051B (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITMI910491A IT1249051B (it) 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5
PCT/EP1992/000338 WO1992014491A1 (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies
EP92904825A EP0577612A1 (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies
AU12088/92A AU1208892A (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI910491A IT1249051B (it) 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5

Publications (3)

Publication Number Publication Date
ITMI910491A0 ITMI910491A0 (it) 1991-02-26
ITMI910491A1 ITMI910491A1 (it) 1992-08-26
IT1249051B true IT1249051B (it) 1995-02-11

Family

ID=11358745

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI910491A IT1249051B (it) 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5

Country Status (4)

Country Link
EP (1) EP0577612A1 (it)
AU (1) AU1208892A (it)
IT (1) IT1249051B (it)
WO (1) WO1992014491A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
IL316155A (en) 2017-11-29 2024-12-01 Heidelberg Pharma Res Compositions and Methods for the Depletion of CD5(PLUS) CELLS
AU2020263959B2 (en) 2019-04-24 2026-01-22 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363799A (en) * 1979-03-20 1982-12-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human T cells, and methods for preparing same
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
DE3581210D1 (de) * 1985-03-04 1991-02-07 Dana Farber Cancer Inst Inc Immunotoxin und herstellung.
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
EP0397798A4 (en) * 1988-02-03 1991-10-30 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
EP0407399A4 (en) * 1988-02-03 1991-06-19 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
AU3750989A (en) * 1988-06-01 1990-01-05 Cetus Corporation One-step chromatographic purification of immunotoxin conjugates using a thiophilic matrix

Also Published As

Publication number Publication date
ITMI910491A1 (it) 1992-08-26
WO1992014491A1 (en) 1992-09-03
ITMI910491A0 (it) 1991-02-26
AU1208892A (en) 1992-09-15
EP0577612A1 (en) 1994-01-12

Similar Documents

Publication Publication Date Title
EP0636029A4 (en) AGAINST CARCINOMA-ASSOCIATED ANTIQUE ANTIBODIES.
MY104946A (en) Antigen antibody conjugate.
EP0394277A4 (en) Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
ATE46084T1 (de) Immunotoxin-konjugate.
CA2056102A1 (en) Method for the production of antibodies
ATE121787T1 (de) Neuer monoklonaler antikörper gegen menschliches karzinom.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
EP0577580A3 (en) Synthesis of sialo conjugates.
NO924103D0 (no) Anvendelse av antistoffholdig preparater for immunundertrykkelse
DK0560912T3 (da) Bindingsstedsspecifik konjugering af immunoglobuliner og påviselige markører
ITRM920457A0 (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana.
BG40318A3 (bg) Метод за получаване на имуноглобулинови производни на виндезина
IT1249051B (it) Immunotossina da anticorpi monoclonali anti-cd5
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
GB2192185B (en) Monoclonal antibodies to pseudomonas aeruginosa flagella
DK0439048T3 (da) Monoklonalt antistof, som genkender en anthracyclinglycosidspecifik epitop, og hybridoma, der udskiller dette antistof
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
EP0511300A4 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
EP0585364A4 (en) THE ANTIQUE CTAA 81AV78 RECOGNIZED BY THE MONOCLONAL HUMAN ANTIBODY 81AV78.
FR2422656A1 (fr) Acetals et cetals cycliques utilisables en parfumerie
FI870482A7 (fi) Suojaavat ihmisen monoklonaaliset vasta-aineet Pseudomonas aeruginosan eksotoksiini A:lle.
ATE132906T1 (de) Neuartige antiidiotypische monoklonale antikörper
TW349995B (en) Monoclonal anti-IgM antibody conjugated to gelonin
DE69118780D1 (de) Monoklonaler Antikörper, der spezifisch mit dem humanen Perforin reagiert

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960227